Add to Watchlist
View Current for OCGN
View SuperFeed for OCGN
View Charts for OCGN
Add or remove $OCGN from your watchlists:
Hang tight! We're updating your watchlist data. This might take a minute...
You have not created a stock watchlist.
Create one now to track $OCGN!
Done
Manage Watchlists
Ocugen Inc
Health Care
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline…
more
Conversation Volume
Last 60 days
There is not enough conversation volume about this stock
Key Opinion Leaders
Strongest 30-day focus on $OCGN by total mentions
Real-time Chart
Price Chart for $OCGN
Conviction History
Bullish vs Bearish Conviction over the last 30 days.
This color denotes Market Hours (US/Eastern)
There is not enough conversation volume about this stock
Thread Explorer
Explore popular threads around $OCGN
There are no threads for this stock
Chart Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Rarely do we see this kind of divergence between value ($SPYV = black line) and growth ($SPYG = red line). Check it out this 5 year chart...
Go to Chart Explorer
Latest News
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Today
Past 7 days
Past 30 days
Past 60 days
Custom
Company Profile
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Market Cap Type: Small
Close
Date,Time,Temperature
2024-03-25,13,0.6955999732017517
2024-03-25,14,0
2024-03-25,15,0
2024-03-25,16,0
2024-03-25,17,0
2024-03-25,18,0
2024-03-25,19,0
2024-03-25,20,0
2024-03-25,21,0
2024-03-25,22,0
2024-03-25,23,0
2024-03-26,0,0
2024-03-26,1,0
2024-03-26,2,0
2024-03-26,3,0
2024-03-26,4,0
2024-03-26,5,0
2024-03-26,6,0
2024-03-26,7,0
2024-03-26,8,0
2024-03-26,9,0
2024-03-26,10,0
2024-03-26,11,0
2024-03-26,12,0
2024-03-26,13,0
2024-03-26,14,0
2024-03-26,15,0
2024-03-26,16,0
2024-03-26,17,0
2024-03-26,18,0
2024-03-26,19,0
2024-03-26,20,0
2024-03-26,21,0
2024-03-26,22,0
2024-03-26,23,0
2024-03-27,0,0
2024-03-27,1,0
2024-03-27,2,0
2024-03-27,3,0
2024-03-27,4,0
2024-03-27,5,0
2024-03-27,6,0
2024-03-27,7,0
2024-03-27,8,0
2024-03-27,9,0
2024-03-27,10,0
2024-03-27,11,0
2024-03-27,12,0
2024-03-27,13,0
2024-03-27,14,0
2024-03-27,15,0
2024-03-27,16,0
2024-03-27,17,0
2024-03-27,18,0
2024-03-27,19,0
2024-03-27,20,0
2024-03-27,21,0
2024-03-27,22,0
2024-03-27,23,0
2024-03-28,0,0
2024-03-28,1,0
2024-03-28,2,0
2024-03-28,3,0
2024-03-28,4,0
2024-03-28,5,0
2024-03-28,6,0
2024-03-28,7,0
2024-03-28,8,0
2024-03-28,9,0
2024-03-28,10,0
2024-03-28,11,0
2024-03-28,12,0
2024-03-28,13,0
2024-03-28,14,0
2024-03-28,15,0
2024-03-28,16,0
2024-03-28,17,0
2024-03-28,18,0
2024-03-28,19,0
2024-03-28,20,0
2024-03-28,21,0
2024-03-28,22,0
2024-03-28,23,0
2024-03-29,0,0
2024-03-29,1,0
2024-03-29,2,0
2024-03-29,3,0
2024-03-29,4,0
2024-03-29,5,0
2024-03-29,6,0
2024-03-29,7,0
2024-03-29,8,0
2024-03-29,9,0
2024-03-29,10,0
2024-03-29,11,0
2024-03-29,12,0
2024-03-29,13,0
2024-03-29,14,0
2024-03-29,15,0
2024-03-29,16,0
2024-03-29,17,0
2024-03-29,18,0
2024-03-29,19,0
2024-03-29,20,0
2024-03-29,21,0
2024-03-29,22,0
2024-03-29,23,0
2024-03-30,0,0
2024-03-30,1,0
2024-03-30,2,0
2024-03-30,3,0
2024-03-30,4,0
2024-03-30,5,0
2024-03-30,6,0
2024-03-30,7,0
2024-03-30,8,0
2024-03-30,9,0
2024-03-30,10,0
2024-03-30,11,0
2024-03-30,12,0
2024-03-30,13,0
2024-03-30,14,0
2024-03-30,15,0
2024-03-30,16,0
2024-03-30,17,0
2024-03-30,18,0
2024-03-30,19,0
2024-03-30,20,0
2024-03-30,21,0
2024-03-30,22,0
2024-03-30,23,0
2024-03-31,0,0
2024-03-31,1,0
2024-03-31,2,0
2024-03-31,3,0
2024-03-31,4,0
2024-03-31,5,0
2024-03-31,6,0
2024-03-31,7,0
2024-03-31,8,0
2024-03-31,9,0
2024-03-31,10,0
2024-03-31,11,0
2024-03-31,12,0
2024-03-31,13,0
2024-03-31,14,0
2024-03-31,15,0
2024-03-31,16,0
2024-03-31,17,0
2024-03-31,18,0
2024-03-31,19,0
2024-03-31,20,0
2024-03-31,21,0
2024-03-31,22,0
2024-03-31,23,0
2024-04-01,0,0
2024-04-01,1,0
2024-04-01,2,0
2024-04-01,3,0
2024-04-01,4,0
2024-04-01,5,0
2024-04-01,6,0
2024-04-01,7,0
2024-04-01,8,0
2024-04-01,9,0
2024-04-01,10,0
2024-04-01,11,0
2024-04-01,12,0
2024-04-01,13,0
2024-04-01,14,0
2024-04-01,15,0
2024-04-01,16,0
2024-04-01,17,0
2024-04-01,18,0
2024-04-01,19,0
2024-04-01,20,0
2024-04-01,21,0
2024-04-01,22,0
2024-04-01,23,0
2024-04-02,0,0
2024-04-02,1,0
2024-04-02,2,0
2024-04-02,3,0
2024-04-02,4,0
2024-04-02,5,0
2024-04-02,6,0
2024-04-02,7,0
2024-04-02,8,0
2024-04-02,9,0
2024-04-02,10,0
2024-04-02,11,0
2024-04-02,12,0
2024-04-02,13,0
2024-04-02,14,0
2024-04-02,15,0
2024-04-02,16,0
2024-04-02,17,0
2024-04-02,18,0
2024-04-02,19,0
2024-04-02,20,0
2024-04-02,21,0
2024-04-02,22,0
2024-04-02,23,0
2024-04-03,0,0
2024-04-03,1,0
2024-04-03,2,0
2024-04-03,3,0
2024-04-03,4,0
2024-04-03,5,0
2024-04-03,6,0
2024-04-03,7,0
2024-04-03,8,0
2024-04-03,9,0
2024-04-03,10,0
2024-04-03,11,0
2024-04-03,12,0
2024-04-03,13,0
2024-04-03,14,0
2024-04-03,15,0
2024-04-03,16,0
2024-04-03,17,0
2024-04-03,18,0
2024-04-03,19,0
2024-04-03,20,0
2024-04-03,21,0
2024-04-03,22,0
2024-04-03,23,0
2024-04-04,0,0
2024-04-04,1,0
2024-04-04,2,0
2024-04-04,3,0
2024-04-04,4,0
2024-04-04,5,0
2024-04-04,6,0
2024-04-04,7,0
2024-04-04,8,0
2024-04-04,9,0
2024-04-04,10,0
2024-04-04,11,0
2024-04-04,12,0
2024-04-04,13,0
2024-04-04,14,0
2024-04-04,15,0
2024-04-04,16,0
2024-04-04,17,0
2024-04-04,18,0
2024-04-04,19,0
2024-04-04,20,0
2024-04-04,21,0
2024-04-04,22,0
2024-04-04,23,0
2024-04-05,0,0
2024-04-05,1,0
2024-04-05,2,0
2024-04-05,3,0
2024-04-05,4,0
2024-04-05,5,0
2024-04-05,6,0
2024-04-05,7,0
2024-04-05,8,0
2024-04-05,9,0
2024-04-05,10,0
2024-04-05,11,0
2024-04-05,12,0
2024-04-05,13,0
2024-04-05,14,0
2024-04-05,15,0
2024-04-05,16,0
2024-04-05,17,0
2024-04-05,18,0
2024-04-05,19,0
2024-04-05,20,0
2024-04-05,21,0
2024-04-05,22,0
2024-04-05,23,0
2024-04-06,0,0
2024-04-06,1,0
2024-04-06,2,0
2024-04-06,3,0
2024-04-06,4,0
2024-04-06,5,0
2024-04-06,6,0
2024-04-06,7,0
2024-04-06,8,0
2024-04-06,9,0
2024-04-06,10,0
2024-04-06,11,0
2024-04-06,12,0
2024-04-06,13,0
2024-04-06,14,0
2024-04-06,15,0
2024-04-06,16,0
2024-04-06,17,0
2024-04-06,18,0
2024-04-06,19,0
2024-04-06,20,0
2024-04-06,21,0
2024-04-06,22,0
2024-04-06,23,0
2024-04-07,0,0
2024-04-07,1,0
2024-04-07,2,0
2024-04-07,3,0
2024-04-07,4,0
2024-04-07,5,0
2024-04-07,6,0
2024-04-07,7,0
2024-04-07,8,0
2024-04-07,9,0
2024-04-07,10,0
2024-04-07,11,0
2024-04-07,12,0
2024-04-07,13,0
2024-04-07,14,0
2024-04-07,15,0
2024-04-07,16,0
2024-04-07,17,0
2024-04-07,18,0
2024-04-07,19,0
2024-04-07,20,0
2024-04-07,21,0
2024-04-07,22,0
2024-04-07,23,0
2024-04-08,0,0
2024-04-08,1,0
2024-04-08,2,0
2024-04-08,3,0
2024-04-08,4,0
2024-04-08,5,0
2024-04-08,6,0
2024-04-08,7,0
2024-04-08,8,0.3612000048160553